מחקרים קליניים איבניטי FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab 17 במאי 2018 מחקר FRAME Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis 12 באוקטובר 2017 מחקר ARCH Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial 30 בספטמבר 2017 מחקר Structure FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab 17 במאי 2018 מחקר FRAME Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis 12 באוקטובר 2017 מחקר ARCH Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial 30 בספטמבר 2017 מחקר Structure
